Cytokine Release Syndrome

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null